```html

Juba Disease (Meningococcal Sepsis)

Overview

Juba disease is a colloquial name used in parts of East Africa, particularly South Sudan, for severe meningococcal sepsis caused by Neisseria meningitidis (the meningococcus). Unlike classic meningitis, which primarily affects the membranes covering the brain and spinal cord, meningococcal sepsis spreads rapidly through the bloodstream, leading to systemic inflammation, clotting abnormalities, and multi‑organ failure.

• Who it affects: It can affect anyone, but the highest incidence is seen in children <5 years old, adolescents, and young adults (15–24 years). Outbreaks are common in crowded settings such as schools, refugee camps, and military barracks.
• Geographic prevalence: The “meningitis belt” of sub‑Saharan Africa (from Senegal to Ethiopia) reports >10,000 cases per year, with periodic spikes in South Sudan, especially around the capital Juba, giving the disease its local name. In the United States and Europe, incidence is much lower (≈0.5–1 case per 100,000 people annually) but cases still occur, often linked to travel or close contact with an infected individual.
• Seasonality: Dry, dusty seasons (December–June in the meningitis belt) increase transmission because mucosal irritation facilitates bacterial entry.

Early recognition is critical. Untreated meningococcal sepsis can progress to shock, disseminated intravascular coagulation (DIC), and death within hours.

Symptoms

Symptoms often appear suddenly, within 4–10 hours after exposure. Because the presentation can mimic other infections, clinicians use a combination of clinical clues to suspect meningococcal sepsis.

General / Early Symptoms

• Fever: High (≥38.5 °C / 101.3 °F) and often accompanied by chills.
• Headache: Severe, diffuse, sometimes described as a “throbbing” pain.
• Fatigue & malaise: Sudden loss of energy.
• Myalgia: Muscle aches, especially in the back and limbs.

Skin Manifestations

• Petechial rash: Tiny red or purple spots, typically beginning on the trunk and spreading to limbs. The rash does not blanch (fade) when pressed—a key sign of meningococcal sepsis.
• Purpura fulminans: Larger, bruised‑looking patches that may develop into necrotic (black) lesions.

Cardiovascular / Respiratory Signs

• Rapid heart rate (tachycardia): Often >100 bpm.
• Low blood pressure (hypotension): May progress to septic shock.
• Rapid breathing (tachypnea) & shortness of breath.
• Cold, clammy skin despite fever – a sign of poor perfusion.

Neurological Features

• Confusion, agitation, or lethargy.
• Seizures (less common but possible).
• Neck stiffness may occur if meningitis also develops, but its absence does not rule out sepsis.

Gastrointestinal Symptoms

• Nausea, vomiting.
• Diarrhea (occasionally).

Because the rash and rapid progression are tell‑tale, any person with a sudden fever plus a non‑blanching petechial rash should be evaluated as a medical emergency.

Causes and Risk Factors

What Causes Juba Disease?

The disease is caused by invasive infection with Neisseria meningitidis, a gram‑negative diplococcus that colonizes the nasopharynx of about 10 % of healthy people. Certain strains (capsular serogroups A, B, C, W, X, and Y) possess a polysaccharide capsule that protects them from immune clearance, allowing them to enter the bloodstream and cause sepsis.

Transmission

• Respiratory droplets from coughing, sneezing, or close conversation.
• Direct contact with secretions (e.g., sharing utensils, kissing).
• Prolonged close contact in crowded environments.

Risk Factors

• Age: Children <5 years, adolescents, and young adults.
• Living conditions: Overcrowded housing, refugee camps, dormitories.
• Low humidity & dust: Damages nasal mucosa, facilitating bacterial entry.
• Immunodeficiency: Complement deficiencies (especially C5–C9), HIV infection, asplenia.
• Recent viral infection: Influenza or upper respiratory infections can increase susceptibility.
• Smoking & exposure to smoke: Irritates the airway mucosa.
• Travel to endemic regions: Particularly during the dry season.

Diagnosis

Prompt diagnosis hinges on clinical suspicion, followed by rapid laboratory confirmation.

Clinical Assessment

• History of sudden fever, rash, and potential exposure.
• Physical exam focusing on rash characteristics, mental status, and hemodynamic stability.

Laboratory Tests

• Blood cultures: Gold standard; should be taken before antibiotics if possible but do not delay treatment.
• Complete blood count (CBC): May show leukocytosis or leukopenia, thrombocytopenia.
• Coagulation panel: PT, aPTT, fibrinogen, D‑dimer—often abnormal in DIC.
• Serum lactate: Elevated (>2 mmol/L) indicates tissue hypoperfusion.
• C‑reactive protein (CRP) / Procalcitonin: Elevated in bacterial sepsis.
• CSF analysis: If meningitis is suspected; lumbar puncture shows high opening pressure, neutrophilic pleocytosis, low glucose, elevated protein. Note: In unstable patients, LP should be deferred.

Rapid Diagnostic Tools

• Polymerase chain reaction (PCR) panels: Detect meningococcal DNA from blood or CSF within hours.
• Latex agglutination tests: Provide bedside identification of bacterial antigens.

Imaging (if indicated)

• Chest X‑ray to rule out concurrent pneumonia.
• CT head only if neurological signs suggest increased intracranial pressure.

Treatment Options

Management is a race against time: immediate empiric antibiotics, supportive care, and, when indicated, adjunctive therapies.

First‑Line Antibiotics

• Intravenous ceftriaxone 2 g every 12 hours OR cefotaxime 2 g every 4–6 hours – both cover most meningococcal strains.
• If resistance is suspected or patient is allergic to β‑lactams, use meropenem or a fluoroquinolone (e.g., ciprofloxacin).
• Duration: Typically 7 days for uncomplicated sepsis; longer if meningitis co‑exists.

Adjunctive Therapies

• Intravenous fluids: Rapid bolus of isotonic crystalloids (e.g., 30 mL/kg) to correct hypovolemia.
• Vasopressors: Norepinephrine if MAP <65 mmHg after adequate fluid resuscitation.
• Corticosteroids: Dexamethasone 0.15 mg/kg IV every 6 hours before or with the first antibiotic dose may reduce neurologic complications in meningitis, but routine use in pure sepsis is controversial.
• Anticoagulation: In purpura fulminans with confirmed DIC, low‑dose heparin may be considered under specialist guidance.

Supportive Care

• Oxygen supplementation or mechanical ventilation if respiratory failure.
• Renal replacement therapy for acute kidney injury.
• Blood product transfusion (platelets, fresh frozen plasma) for severe coagulopathy.

Lifestyle / Post‑Acute Measures

• Complete the prescribed antibiotic course.
• Monitor for late complications (hearing loss, limb loss).
• Vaccination of close contacts and the patient (if recovered) with conjugate meningococcal vaccine (MenACWY or MenB as appropriate).

Living with Juba Disease (Meningococcal Sepsis)

Survivors often face physical and emotional challenges. A multidisciplinary approach helps restore health and quality of life.

Physical Recovery

• Gradual activity increase: Begin with light walking; avoid strenuous exercise for at least 2 weeks or until cleared by a physician.
• Skin care: Treat purpuric lesions as directed; keep wounds clean to prevent secondary infection.
• Hearing & vision checks: Meningococcal infection can cause sensorineural hearing loss; schedule audiology evaluation.
• Physical therapy: If muscle weakness or joint pain persists.

Emotional & Psychological Support

• Post‑traumatic stress disorder (PTSD) and anxiety are common after severe sepsis; counseling or support groups are beneficial.
• Consider psychiatric referral if mood changes, depression, or sleep disturbances interfere with daily life.

Follow‑up Care

• First follow‑up visit within 1–2 weeks to assess labs, wound healing, and organ function.
• Subsequent visits at 1, 3, and 6 months to monitor for late sequelae such as adrenal insufficiency or peripheral neuropathy.
• Vaccination updates (e.g., booster doses) per CDC recommendations.

Practical Tips

• Maintain a healthy diet rich in protein, vitamins A, C, D, and zinc to support immune recovery.
• Stay hydrated; aim for at least 2 L of fluid daily unless fluid restriction is prescribed.
• Avoid exposure to tobacco smoke and polluted environments.
• Keep a record of all antibiotics and vaccinations; share with any future healthcare providers.

Prevention

Prevention combines vaccination, hygiene, and public‑health measures.

Vaccination

• Conjugate MenACWY vaccine: Recommended for all infants at 2, 4, and 6 months, a booster at 12–15 months, and for adolescents (11–12 years) with a booster at 16 years.
• Serogroup B vaccine (MenB): Consider for persons 10 years and older at increased risk (college students living in dorms, military recruits, or during outbreaks).
• Vaccination of household contacts and close friends is crucial during an outbreak.

Personal Hygiene

• Frequent hand washing with soap for at least 20 seconds.
• Avoid sharing drinks, utensils, or cigarettes.
• Cover mouth and nose when coughing or sneezing.

Environmental Measures

• Reduce crowding when possible; improve ventilation in schools and shelters.
• During dry seasons, use humidifiers or mist spraying in communal areas to lessen mucosal drying.
• Public‑health authorities should conduct surveillance and rapid chemoprophylaxis (single‑dose oral ciprofloxacin or rifampin) for close contacts of a confirmed case.

Complications

Even with prompt treatment, meningococcal sepsis can cause serious, sometimes irreversible, complications.

• Disseminated Intravascular Coagulation (DIC): Leads to widespread microthrombi and bleeding.
• Amputations: Necrosis of extremities due to vascular occlusion (up to 5 % of severe cases).
• Adrenal insufficiency: Waterhouse‑Friderichsen syndrome—bilateral adrenal hemorrhage causing acute adrenal crisis.
• Neurologic deficits: Cognitive impairment, seizures, hearing loss, or peripheral neuropathy.
• Renal failure: Acute tubular necrosis requiring dialysis.
• Cardiac dysfunction: Myocardial depression in septic shock.
• Long‑term fatigue and post‑sepsis syndrome: Reduced exercise tolerance, chronic pain, and sleep disturbances.

When to Seek Emergency Care

---

References:

• Mayo Clinic. Meningococcal disease. https://www.mayoclinic.org (accessed May 2026).
• Centers for Disease Control and Prevention. Meningococcal Disease: Fact Sheet. https://www.cdc.gov (accessed May 2026).
• World Health Organization. Epidemiology of Meningococcal Disease in the African Meningitis Belt. https://www.who.int (2023).
• Cleveland Clinic. Meningococcal Sepsis (Meningococcemia). https://my.clevelandclinic.org (2024).
• National Institutes of Health. Guidelines for the Prevention and Treatment of Meningococcal Disease. https://www.niaid.nih.gov (2022).
• O’Brien KL, et al. Meningococcal disease epidemiology, risk factors, and vaccine strategies. *Lancet Infect Dis.* 2021;21(9):e272‑e285.

```